» Articles » PMID: 35316220

NOGOB Receptor Deficiency Increases Cerebrovascular Permeability and Hemorrhage Via Impairing Histone Acetylation-mediated CCM1/2 Expression

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2022 Mar 22
PMID 35316220
Authors
Affiliations
Soon will be listed here.
Abstract

The loss function of cerebral cavernous malformation (CCM) genes leads to most CCM lesions characterized by enlarged leaking vascular lesions in the brain. Although we previously showed that NOGOB receptor (NGBR) knockout in endothelial cells (ECs) results in cerebrovascular lesions in the mouse embryo, the molecular mechanism by which NGBR regulates CCM1/2 expression has not been elucidated. Here, we show that genetic depletion of Ngbr in ECs at both postnatal and adult stages results in CCM1/2 expression deficiency and cerebrovascular lesions such as enlarged vessels, blood-brain-barrier hyperpermeability, and cerebral hemorrhage. To reveal the molecular mechanism, we used RNA-sequencing analysis to examine changes in the transcriptome. Surprisingly, we found that the acetyltransferase HBO1 and histone acetylation were downregulated in NGBR-deficient ECs. The mechanistic studies elucidated that NGBR is required for maintaining the expression of CCM1/2 in ECs via HBO1-mediated histone acetylation. ChIP-qPCR data further demonstrated that loss of NGBR impairs the binding of HBO1 and acetylated histone H4K5 and H4K12 on the promotor of the CCM1 and CCM2 genes. Our findings on epigenetic regulation of CCM1 and CCM2 that is modulated by NGBR and HBO1-mediated histone H4 acetylation provide a perspective on the pathogenesis of sporadic CCMs.

Citing Articles

Appraising histone H4 lysine 5 lactylation as a novel biomarker in breast cancer.

Zhu Y, Fu Y, Liu F, Yan S, Yu R Sci Rep. 2025; 15(1):8205.

PMID: 40065036 PMC: 11893895. DOI: 10.1038/s41598-025-92666-6.


Construction of a novel platelet‑related gene risk model to predict the prognosis and drug response in virus‑related hepatocellular carcinoma.

Zhang J, Xiang H, Jiang L, Wang M, Yang G Oncol Lett. 2024; 28(6):592.

PMID: 39417040 PMC: 11481168. DOI: 10.3892/ol.2024.14725.


Novel Factors Regulating Proliferation, Migration, and Differentiation of Fibroblasts, Keratinocytes, and Vascular Smooth Muscle Cells during Wound Healing.

Smith J, Rai V Biomedicines. 2024; 12(9).

PMID: 39335453 PMC: 11429312. DOI: 10.3390/biomedicines12091939.


Insights into the regulatory role of epigenetics in moyamoya disease: Current advances and future prospectives.

Xu S, Chen T, Yu J, Wan L, Zhang J, Chen J Mol Ther Nucleic Acids. 2024; 35(3):102281.

PMID: 39188306 PMC: 11345382. DOI: 10.1016/j.omtn.2024.102281.


Trifluoperazine regulates blood-brain barrier permeability via the MLCK/p-MLC pathway to promote ischemic stroke recovery.

Zhang W, Chen S, Ma B, Ding Y, Liu X, He C iScience. 2024; 27(3):109156.

PMID: 38439960 PMC: 10910233. DOI: 10.1016/j.isci.2024.109156.


References
1.
Verlaan D, Laurent S, Rouleau G, Siegel A . No CCM2 mutations in a cohort of 31 sporadic cases. Neurology. 2004; 63(10):1979. DOI: 10.1212/01.wnl.0000144195.55540.9d. View

2.
Yan M, Marsden P . Epigenetics in the Vascular Endothelium: Looking From a Different Perspective in the Epigenomics Era. Arterioscler Thromb Vasc Biol. 2015; 35(11):2297-306. PMC: 4618795. DOI: 10.1161/ATVBAHA.115.305043. View

3.
Song L, Ge S, Pachter J . Caveolin-1 regulates expression of junction-associated proteins in brain microvascular endothelial cells. Blood. 2006; 109(4):1515-23. PMC: 1794065. DOI: 10.1182/blood-2006-07-034009. View

4.
Clatterbuck R, Eberhart C, Crain B, Rigamonti D . Ultrastructural and immunocytochemical evidence that an incompetent blood-brain barrier is related to the pathophysiology of cavernous malformations. J Neurol Neurosurg Psychiatry. 2001; 71(2):188-92. PMC: 1737494. DOI: 10.1136/jnnp.71.2.188. View

5.
Gross B, Du R . Cerebral cavernous malformations: natural history and clinical management. Expert Rev Neurother. 2015; 15(7):771-7. DOI: 10.1586/14737175.2015.1055323. View